

## Anti-CXCR4/CD184 Antibody (Ulocuplumab)

### Introduction

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis in cancer cells and can inhibit CXCL12-mediated migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation. Ulocuplumab shows anti-tumor activity in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and multiple myeloma transplant models.

### Product parameters

Alternative Names	MDX-1338, BMS-936564, F7
Target Accession	P61073
Target	CXCR4 / CD184
CAS number	1375830-34-4
Molecular Weight	150 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human CXCR4 / CD184 Romas cells were stained with Anti-CXCR4/CD184 Antibody (Ulocuplumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=5.915 nM.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

## Note

1. This product is for scientific research use only.



### APEx BIO Technology

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

